Featured Article

March 25, 2024

CluePoints on overcoming scepticism and the benefits of AI to optimize trial strategies

Patrick Hughes, co-founder and chief commercial officer of Cluepoints and OSP caught up for an in-person discussion during SCOPE 2024 to find out what developments the company had been working on and how they are benefiting from using AI.

Guide

A Comprehensive Guide to Adaptive Site Monitoring

Blog

Decoding ICH E6(R3): What It Means for Risk-Based Quality Management (RBQM)

Authors: Frederic Blais, Jelena Pasimisina, Melissa Thomas ICH E6(R3) provides greater clarity on proactively designing quality...

Blog

10 Steps for Practical RBQM Implementation for Your Business

Many clinical trial Sponsors and Contract Research Organizations (CROs) realize the great benefits of Risk-Based Quality...

Blog

QTLs: Where Are We, And How Much Further Can We Go?

Quality Tolerance Limits (QTLs) represent a significant advancement in clinical trial research, aimed at proactively identifying...